Literature DB >> 2782767

The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago "COPD" series.

B Burrows1.   

Abstract

Recently reported data from a general population study in Tucson, Arizona have shown that subjects who have an "asthmatic bronchitic" type of chronic airways obstruction have a much more benign course than equally impaired subjects who have the typical smoking-induced, and presumably emphysematous, form of disease. These data are reviewed briefly. Findings in these subjects are then compared with those in "COPD" patients enrolled in an "emphysema clinic" in Chicago many years ago; patients with asthmatic features had been systematically excluded from the Chicago series. The rate of decline in FEV1 and mortality of Arizona subjects considered to have "typical COPD" were remarkably similar to those in the Chicago series after accounting for age and initial FEV1, but Arizona subjects with features suggesting "chronic asthmatic bronchitis" had a much more favorable prognosis than either of the "COPD" groups. These different forms of chronic airways obstruction should be distinguished in clinical or epidemiologic studies of airways obstructive disorders.

Entities:  

Mesh:

Year:  1989        PMID: 2782767     DOI: 10.1164/ajrccm/140.3_Pt_2.S92

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  2 in total

1.  Spirometry is underused in the diagnosis and monitoring of patients with chronic obstructive pulmonary disease (COPD).

Authors:  Wai Cho Yu; Sau Nga Fu; Emily Lai-Bun Tai; Yiu Cheong Yeung; Kwok Chu Kwong; Yui Chang; Cheuk Ming Tam; Yuk Kwan Yiu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-08-26

2.  Is COPD a Progressive Disease? A Long Term Bode Cohort Observation.

Authors:  Juan P de-Torres; Jose M Marín; Víctor Pinto-Plata; Miguel Divo; Pablo Sanchez-Salcedo; Jorge Zagaceta; Javier J Zulueta; Juan Berto; Carlos Cabrera; Bartolome R Celli; Ciro Casanova
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.